-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AKP-11 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AKP-11 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AKP-11 in Atopic Dermatitis (Atopic Eczema) Drug Details: AKP-11 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Betamethasone + Calcipotriene) in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Betamethasone + Calcipotriene) in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Betamethasone + Calcipotriene) in Plaque Psoriasis (Psoriasis Vulgaris)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-4901 in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-4901 in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-4901 in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AKP-11
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AKP-11 Drug Details AKP-11 is under development for the treatment of pain and inflammation...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (betamethasone + calcipotriene)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (betamethasone + calcipotriene) Drug Details AKP-02 is under development for the treatment of plaque...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AK-1780
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AK-1780 Drug Details AKP-23494954 (RQ-00466479) is under development for the treatment of neuropathic pain....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ASP-4901
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ASP-4901 Drug Details ASP-4901 (AKP-002, CRD-733) is under development for cardiovascular indications such as...
-
Product Insights
Benign Prostatic Hyperplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Benign Prostatic Hyperplasia (BPH) include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, and difficulty starting a urine stream. The Benign Prostatic Hyperplasia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Sector Analysis
Pruritus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants. The Pruritus- Drugs in Development research report provides a comprehensive overview on the therapeutics under...
-
Product Insights
Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections. The Alopecia drugs in development market research report provides an overview of the Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target,...